Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China's BGI and Healthlink Invest and Make Deal with UK's Congenica

publication date: Apr 27, 2017
Congenica, a Cambridge, UK company that offers clinical genomics interpretation software for inherited diseases, completed a Series B funding from two China-based investors -- BGI Genomics and Healthlink Capital -- along with Future Planet Capital. BGI Genomics and Healthlink also signed up to use Congenica’s enterprise software, Sapientia™, in their China clinical diagnostic labs. Financial details were not disclosed, but Congenica did announce an earlier $10 million closing of its Series B round with other investors in February. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital